(continued)
Amorcyte Inc is a therapeutics company pursuing cell based therapies for cardiovascular diseases, reimbursable on a commercial scale for widespread clinical use. Amorcyte was incorporated in May 2005 and received approval for its Phase I trial in September 2005. Watch for the launch of www.amorcyte.com.
s PA Early Stage Partners, founded in 1997, is an active and experienced family of venture capital funds that seek portfolio companies located in the corridor from New York to Washington, D.C. PA Early Stage invests in early stage Technology and Life Sciences companies, typically as a lead or co-lead investor. PA Early Stage currently has approximately 30 active portfolio companies and more than $235 million under management across three venture funds.
It is estimated that each year there are approximately 1.1 million instances of acute myocardial infarctions, 12 million cases of chronic ischemia and 5 million occurrences of congestive heart failure in the United States. A significant percentage of these patients may benefit from additional therapies to ameliorate the symptoms of their disease. Therapies like those being developed by Amorcyte are under active investigation to determine safety and efficacy.